108 Participants Needed

Total vs Reverse Shoulder Arthroplasty for Shoulder Osteoarthritis

(SERVASA Trial)

Recruiting at 5 trial locations
KM
PL
Overseen ByPeter Lapner Lapner, MD
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Ottawa Hospital Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The trial aims to identify the best surgical option for individuals with shoulder osteoarthritis by comparing total shoulder arthroplasty (TSA) and reverse shoulder arthroplasty (RSA). TSA replaces the shoulder's worn-out joint with artificial parts, while RSA switches the positions of the joint's ball and socket. The trial seeks participants who have had shoulder osteoarthritis for over six months, have not found relief with medications or therapy, and experience significant pain and disability. As an unphased trial, it offers participants the chance to contribute to valuable research that may enhance surgical outcomes for future patients.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves surgery, it's best to discuss your medications with the study team or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that both Reverse Shoulder Arthroplasty (RSA) and Total Shoulder Arthroplasty (TSA) are generally safe and effective. Studies have found that RSA significantly improves shoulder movement and reduces pain. Serious complications within the first 90 days are rare, and patients often experience better movement and less pain over time.

For TSA, patients can expect good long-term results. Research indicates that most implants last a long time, with a survival rate of 84%. TSA also typically leads to improved shoulder function and pain relief.

Both procedures have been thoroughly reviewed and compared. While each offers benefits, both are viable options for individuals with shoulder osteoarthritis. Safety data suggests that most patients tolerate these treatments well.12345

Why are researchers excited about this trial?

Researchers are excited about these shoulder arthroplasty treatments because they offer innovative approaches to address shoulder osteoarthritis. Total Shoulder Arthroplasty (TSA) replaces the worn-out ball and socket joint with prosthetic components, providing a more natural joint movement. In contrast, Reverse Shoulder Arthroplasty (RSA) changes the orientation of the joint, potentially improving stability and function for patients with damaged rotator cuffs. Additionally, the use of an augmented glenoid implantation in TSA aims to enhance joint support and longevity, potentially offering better outcomes for patients with severe joint erosion. These advancements could lead to improved range of motion and reduced pain compared to traditional shoulder replacement options.

What evidence suggests that this trial's treatments could be effective for shoulder osteoarthritis?

Research has shown that both reverse shoulder replacement (RSA) and total shoulder replacement (TSA) effectively treat shoulder arthritis. In this trial, participants will receive either the RSA or TSA treatment. RSA significantly improves shoulder movement and reduces pain compared to no surgery, with 88% of patients avoiding another surgery for at least 10 years. For TSA, studies indicate that patients experience better shoulder function after six months, with improvements lasting for years. Both surgeries offer good options, with RSA being particularly suitable for older adults. The best choice depends on each person's specific needs and health conditions.13678

Who Is on the Research Team?

Ottawa Hospital Research Institute

Peter Lapner, MD

Principal Investigator

The Ottawa Hospital

Are You a Good Fit for This Trial?

This trial is for people over 65 with severe shoulder osteoarthritis who haven't improved after 6 months of non-surgical treatments like physiotherapy and painkillers. It's not for those with a life expectancy under a year, high surgery risk, psychiatric conditions affecting consent, pregnancy, or previous shoulder surgeries on the affected side.

Inclusion Criteria

I am undergoing physiotherapy with exercises and treatments like ultrasound.
I am 65 years old or older.
My shoulder joint shows advanced cartilage loss.
See 6 more

Exclusion Criteria

I do not have a major illness that would give me less than a year to live.
Pregnancy
Unwilling to be followed for the duration of the study
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Surgery

Participants undergo either Total Shoulder Arthroplasty (TSA) or Reverse Shoulder Arthroplasty (RSA) procedures

1 day
1 visit (in-person)

Post-operative Follow-up

Participants are monitored for functional outcomes and quality of life improvements using various assessment tools

24 months
Multiple visits (in-person and virtual) over 24 months

Long-term Follow-up

Participants are assessed for long-term outcomes, including survivorship of components and adverse events

5 years
Annual visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Reverse Shoulder Arthroplasty
  • Total Shoulder Arthroplasty
  • Total Shoulder Arthroplasty + Augmented Glenoid Implantation
Trial Overview The study is comparing two types of shoulder replacement surgeries: Total Shoulder Arthroplasty (TSA) and Reverse Shoulder Arthroplasty (RSA). Participants will be randomly assigned to one of these surgical options to see which is better for treating advanced glenohumeral osteoarthritis in seniors.
How Is the Trial Designed?
2Treatment groups
Active Control
Group I: Total Shoulder Arthroplasty (anatomic)Active Control1 Intervention
Group II: Reverse Shoulder ArthroplastyActive Control1 Intervention

Reverse Shoulder Arthroplasty is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Reverse Shoulder Arthroplasty for:
🇺🇸
Approved in United States as Reverse Shoulder Arthroplasty for:
🇨🇦
Approved in Canada as Reverse Shoulder Arthroplasty for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ottawa Hospital Research Institute

Lead Sponsor

Trials
585
Recruited
3,283,000+

Published Research Related to This Trial

The study found a high revision-free survivorship rate of 93% at 5 years for patients who underwent reverse shoulder arthroplasty (RSA) using a medialized glenoid and lateralized onlay-type humerus implant, based on a review of 526 surgeries with an average follow-up of 4.83 years.
Instability was identified as the most common reason for revision surgeries (1.9%), and patients who had prior shoulder surgeries were more likely to require revisions after RSA, indicating that previous surgeries may increase the risk of complications.
Survivorship of a Medialized Glenoid and Lateralized Onlay Humerus Reverse Shoulder Arthroplasty Is High at Midterm Follow-up.Rauck, RC., Eck, EP., Chang, B., et al.[2022]
In a study of 166 revision shoulder arthroplasty cases with an average follow-up of 1 year, it was found that revisions of reverse shoulder arthroplasty (RSA) to another RSA had the highest repeat revision rate at 32%, indicating a higher risk of complications compared to other types of revisions.
Despite a notable long-term complication rate, the immediate perioperative outcomes for revision surgeries were similar to those of primary shoulder arthroplasties, suggesting that revisions can be performed safely and may be considered in future healthcare models.
Trends in outcomes following aseptic revision shoulder arthroplasty.Stauffer, TP., Goltz, DE., Wickman, JR., et al.[2023]
In a study of 216 shoulders undergoing reverse total shoulder arthroplasty, glenoid bone defects were managed effectively with modified surgical techniques, including the use of bone grafts in 22 cases, demonstrating that these defects do not prevent successful surgery.
Both groups, those with normal and abnormal glenoids, showed significant improvement in clinical outcomes post-surgery, with no significant differences in American Shoulder and Elbow Surgeons scores, indicating that reverse shoulder arthroplasty is effective regardless of glenoid morphology.
Effects of acquired glenoid bone defects on surgical technique and clinical outcomes in reverse shoulder arthroplasty.Klein, SM., Dunning, P., Mulieri, P., et al.[2022]

Citations

Long-Term Outcomes Following Reverse Total Shoulder ...RTSA can provide satisfactory improvement of pain and function at long-term follow-up mean revision-free survivorship of 88% after 10 years.
Reverse total shoulder replacement versus anatomical ...This study's findings provide reassurance that RTSR is an acceptable alternative to TSR for patients aged 60 years or older with osteoarthritis and intact ...
Short- to medium-term outcomes and future direction of ...Reverse shoulder arthroplasty is associated with significant improvements in shoulder function and pain reduction compared to non-surgical treatments.
Shoulder replacement in the under 55's is anatomical or ...Reverse shoulder replacement can be a viable solution for younger patients with severe shoulder pathology when anatomic TSA is not an option. ...
5.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/38218404/
Outcomes after reverse shoulder arthroplasty for the ...RSA is a successful surgical treatment for GHOA regardless of age. Aside from greater postoperative FE in younger patients, there were no other differences.
Clinical outcomes after reverse shoulder arthroplasty in ...Early published results of RTSA in elderly, low demand patients with cuff tear arthropathy noted reliable improvements in pain, range of motion, and overall ...
Total shoulder arthroplasty versus reverse ...This study aimed to compare TSA and RSA in OA patients with or without rotator cuff damage to better guide clinical decision making.
A systematic review and meta-analysisOur meta-analysis indicates that, for shoulder degenerative diseases, aTSA generally offers superior postoperative efficacy compared with rTSA.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security